| Filed On | Filing |
|---|---|
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 |
| 19 Oct 2026 |
8-K: Regulation FD Disclosure
NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic... |
| 13 Oct 2026 | SCHEDULE 13G |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic... |
| 08 Oct 2026 | SCHEDULE 13D/A |
| 06 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 22 Jun 2026 |
Form 4: Parsey Merdad, Director
Granted 13,562 Non-Qualified Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Peterson Kristine, Director
Granted 13,562 Non-Qualified Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Hohneker John, Director
Granted 13,562 Non-Qualified Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Nolet Chris, Director
Granted 13,562 Non-Qualified Stock Option (right to buy) |
| 22 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 11 May 2026 | 424B5 |
| 11 May 2026 | 8-K: Other Events |
| 11 May 2026 | 10-Q |
| 11 May 2026 | 8-K: Results of Operations and Financial Condition |
| 06 May 2026 | SCHEDULE 13G/A |
| 28 Apr 2026 | ARS |
Loading...
